Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01367613 · ClinicalTrials.gov registry record · Phase 3
Open-Label Treatment Extension of Protocol MNTX 302
A Phase 3 study of Terminal Illness, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT01367613 is a Phase 3 study of Terminal Illness that has completed, run by Bausch Health Americas. The registered enrollment target is 89 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01367613, a Phase 3 study of Terminal Illness, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.
Conditions Studied
Interventions
- DRUG SC Methylnaltrexone
Study Locations (1)
New York
- Progenics Pharmaceuticals, Inc. - Tarrytown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01367613
The ClinicalTrials.gov registry entry for NCT01367613 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Terminal Illness appearing as the primary indexed condition, and to 1 intervention - of which SC Methylnaltrexone is the first listed.
NCT01367613 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01367613 about?
NCT01367613 is a clinical study titled "Open-Label Treatment Extension of Protocol MNTX 302". This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.
What is the current status of trial NCT01367613?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 89 participants. The study started on 2004-03. Estimated completion is 2006-01.
What conditions does trial NCT01367613 study?
This clinical trial studies the following conditions: Terminal Illness.
What interventions are being tested in trial NCT01367613?
The interventions under investigation include: SC Methylnaltrexone (DRUG).
Who is sponsoring clinical trial NCT01367613?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01367613 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Terminal Illness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.